Meridian Clinical Research
Baton Rouge, Louisiana 70809
0 studies enrolling now · 15 studies all time
What they study most
Atopic Dermatitis, Atopic Dermatitis (AD), COVID-19, Dermatitis, Atopic, Healthy Volunteers, Hypertension, Influenza, Human, Pneumococcal Disease, Pruritus, Psoriasis, SARS-CoV-2, SARS-CoV-2 Infection
Studies at this site
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age — Completed
- A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 — Completed
- Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults — Completed
- Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
- Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis — Completed
- Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension — Completed
- Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension — Completed
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) — Completed
- B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis — Completed
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older — Completed
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 — Completed
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
- A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator — Completed
- A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis — Stopped early
- Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis — Completed